BioNTech’s $1 Billion Buyback Gambit: Betting on Cancer While COVID Cash Fades

BioNTech reports Q1 2026 revenue slump to €118M and net loss of €531.9M, but doubles down on oncology with $1B buyback, R&D surge, and key pipeline milestones.

The numbers tell a stark story of transition. BioNTech’s first-quarter 2026 revenue slumped to €118.1 million, a roughly 35% decline from the prior year, as the COVID-19 vaccine boom recedes into memory. The net loss ballooned to €531.9 million, widening from €415.8 million in the same period last year. Yet the Mainz-based biotech is not retreating into cost-cutting mode. Instead, it is doubling down on oncology with a $1 billion share buyback program and a surge in R&D spending that reached €557 million in the quarter alone.

The market’s response was muted at best. Shares closed at €81.50 on Tuesday, slipping below their 50-day moving average and losing about 4% on the session. The stock now trades roughly 20% below its 52-week high of €101.90, and has edged down 1.2% since the start of the year.

A Pipeline Pivot Accelerates

Management is framing this period as a strategic inflection point. Five new pivotal trials have been launched for the immunotherapy candidate Pumitamig, developed in collaboration with Bristol Myers Squibb, targeting indications including breast and lung cancer. Early phase 1b/2a data in non-small cell lung cancer showed a 46% response rate, median progression-free survival of 13.6 months, and overall survival of 27 months.

Another candidate, Gotistobart, has received FDA orphan drug designation. In clinical studies, it reduced the risk of death by 54% compared to the standard chemotherapy docetaxel. The company is positioning for a data-heavy second half of 2026, with six late-stage readouts expected in the coming months.

To free up resources for this oncology push, BioNTech is handing over all COVID vaccine production to partner Pfizer by the end of the year. The restructuring comes with a price tag: manufacturing sites in Idar-Oberstein, Marburg, Tübingen, and Singapore will close by the end of 2027, generating annual savings of roughly €500 million starting in 2029.

Cash Cushion and a Buyback Signal

Despite the operating losses, BioNTech’s balance sheet remains formidable. The company holds €16.8 billion in liquidity, providing ample runway for the multiyear oncology buildout. The board has authorized a share buyback program of up to $1 billion over the next twelve months — a clear signal that management considers the stock undervalued given the pipeline potential.

The full-year 2026 guidance remains unchanged, with revenue forecast between €2.0 billion and €2.3 billion. Research spending is expected to run between €2.2 billion and €2.5 billion, an unusual ratio that underscores how heavily the company is betting on future pipeline success. Management does not expect near-term revenue contributions from oncology this year, meaning the shrinking vaccine sales will continue to fund the research engine for now.

A concrete near-term milestone is already on the calendar: BioNTech plans to file a US approval application for Trastuzumab Pamirtecan in endometrial cancer before the end of 2026.

Founders Prepare Their Exit

The most dramatic change may be in the boardroom. Founders Ugur Sahin and Özlem Türeci will leave the executive board by the end of 2026 to launch a new mRNA company. They will retain their combined stake of roughly 15%, keeping them as major shareholders with continued influence over strategic direction.

Analysts see the long-term oncology potential as significant, with price targets reaching as high as $143 per share. BioNTech is targeting more than 17 late-stage clinical data packages by 2030. Whether the clinical readouts for Pumitamig and other candidates justify the current valuation — and the buyback — will become clearer with the next wave of pivotal data.